Response to SARS-CoV-2 vaccines in patients receiving B-cell modulating antibodies for renal autoimmune disease
Abstract: Background
Effective SARS-CoV-2 vaccination in patients receiving treatment with B-cell depleting agents is challenging. Information on vaccination responses in these patients are a valuable tool to develop efficient vaccination regimens.
Methods
In this single-center retrospective observational study, we report the humoral and cellular response in 34 patients receiving anti-CD20 antibody treatment for renal immune disease.
Results
After base immunization with SARS-CoV-2-vaccines, 92.0% developed a cellular, 32.4% a humoral response. Humoral immunity correlated with B-cell counts and the timespan between anti-CD20 antibody treatment and vaccination. All patients with > 21/µl B-cells, or > 197 days after treatment showed humoral response.
Conclusions
Adequate timing of SARS-CoV-2-vaccinations after anti-CD20 antibody treatment and CD19 measurements are crucial to generate immunity. Awaiting partial B-cell recovery by postponing regularly scheduled anti-CD20 treatment should be considered in patients with stable immune disease.
Trial registration: This study has been retrospectively registered in the German Clinical Trials Register (DRKS00027049) on 29/10/2021
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
BMC infectious diseases. - 22, 1 (2022) , 734, ISSN: 1471-2334
- Event
-
Veröffentlichung
- (where)
-
Freiburg
- (who)
-
Universität
- (when)
-
2022
- DOI
-
10.1186/s12879-022-07722-7
- URN
-
urn:nbn:de:bsz:25-freidok-2296621
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:41 PM CET
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Arnold, Frederic
- Huzly, Daniela
- Tanriver, Yakup
- Welte, Thomas
- Universität
Time of origin
- 2022
Other Objects (12)
Identification of covariates modulating B‐cell repopulation kinetics in subjects receiving rituximab treatment
Editorial: Modulating Cytokines as Treatment for Autoimmune Diseases and Cancer
COVID-19 in patients receiving CD20-depleting immunochemotherapy for B-cell lymphoma
Characterization of the autoimmune B-cell response against ribosome-associated protein L7 in systemic autoimmune diseases
B-cell NHL subtype risk associated with autoimmune conditions and PRS
B-cell recruitment in spontaneous relapsing remitting (RR) experimental autoimmune encephalomyelitis (EAE)
Characterization of Vaccinia virus MVA candidate vaccines mutated in viral genes modulating inflammasome activation
Advantages and Limitations of Integrated Flagellin Adjuvants for HIV-Based Nanoparticle B-Cell Vaccines
Induction of type 1 diabetes using preproinsulin-based vaccines in Experimental Autoimmune Diabetes (EAD)
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
Receiving Tube
Veterinary vaccines
Identification of covariates modulating B‐cell repopulation kinetics in subjects receiving rituximab treatment
Editorial: Modulating Cytokines as Treatment for Autoimmune Diseases and Cancer
COVID-19 in patients receiving CD20-depleting immunochemotherapy for B-cell lymphoma
Characterization of the autoimmune B-cell response against ribosome-associated protein L7 in systemic autoimmune diseases
B-cell NHL subtype risk associated with autoimmune conditions and PRS
B-cell recruitment in spontaneous relapsing remitting (RR) experimental autoimmune encephalomyelitis (EAE)
Characterization of Vaccinia virus MVA candidate vaccines mutated in viral genes modulating inflammasome activation
Advantages and Limitations of Integrated Flagellin Adjuvants for HIV-Based Nanoparticle B-Cell Vaccines
Induction of type 1 diabetes using preproinsulin-based vaccines in Experimental Autoimmune Diabetes (EAD)
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
Receiving Tube
Veterinary vaccines
Identification of covariates modulating B‐cell repopulation kinetics in subjects receiving rituximab treatment
Editorial: Modulating Cytokines as Treatment for Autoimmune Diseases and Cancer
COVID-19 in patients receiving CD20-depleting immunochemotherapy for B-cell lymphoma
Characterization of the autoimmune B-cell response against ribosome-associated protein L7 in systemic autoimmune diseases
B-cell NHL subtype risk associated with autoimmune conditions and PRS
B-cell recruitment in spontaneous relapsing remitting (RR) experimental autoimmune encephalomyelitis (EAE)
Characterization of Vaccinia virus MVA candidate vaccines mutated in viral genes modulating inflammasome activation
Advantages and Limitations of Integrated Flagellin Adjuvants for HIV-Based Nanoparticle B-Cell Vaccines
Induction of type 1 diabetes using preproinsulin-based vaccines in Experimental Autoimmune Diabetes (EAD)
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
Receiving Tube